Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-17
2006-01-17
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S049000, C514S275000, C424S085700
Reexamination Certificate
active
06987103
ABSTRACT:
The present invention concerns a method of treating chronic myelogenous leukemia, a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia in a subject animal, comprising:(a) selecting or identifying an animal suffering from chronic myelogenous leukemia or a related myeloproliferative disorder and showing resistance or intolerance to treatment with STI571; and(b) administering to the animal homoharringtonine.In a preferred embodiment, the animal is a human being.
REFERENCES:
patent: 2003/0148955 (2003-08-01), Pluenneke
Cancer Principles & Practice of Oncology, 5thEdition, published 1997 by Lippincott-Raven, pp 498-509.
Cancer Principles & Practice of Oncology, 6thEdition, published 2001 by Lippincott-Raven, pp 2433-2445.
Tipping et al. Blood, (Nov. 16, 2000), vol. 96, No. 11, Part 1, pp 98a. print. Meeting Info.: 42 Annual Meeting of the American Society of Hematology, San Francisco, California, USA Dec. 1-5, 2000. American Society of Hematology (Abstract Only).
Hagop M. Kantarjian, et al, “Chronic Myeiogenous Leukemia-Progress at the M.D. Anderson Cancer Center over the Past Two Decades and Future Directions: First Emil J. Freireich Award Lecture,” Clinical Cancer Research, vol. 3, Dec. 1997, pp. 2723-2733.
Hagop M. Kantarjian, MD, et al, “Clinical Course and Therapy of Chronic Myelogenous Leukemia with Interferon-Alpha and Chemotherapy,” Biology and Therapy of Chronic Myelogenous Leukemia, vol. 12, No. 1, Feb. 1998, pp. 31-80.
Jorge E. Cortes, MD, et al, “Chronic Myelogenous Leukemia: A Review,” The American Journal of Medicine, vol. 100, May 1996, pp. 555-570.
Stefan Faderl, MD, et al, “Chronic Myelogenous Leukemia: Update on Biology and Treatment,” Oncology, vol. 13, No. 2, Feb. 1999, pp. 169-180.
James N. George, et al, “The Evidence-Based Analysis of Treatment for Chronic Myeloid Leukemia: An Introduction to Its Methods and Clinical Implications,” Blood, vol. 94, No. 5, Sep. 1, 1999, pp. 1515-1517.
Richard T. Silver, et al, “An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea, Interferon, and Allogeneic Bone Marrow Transplatation in Treating the Chronic Phase of Chronic Myleoid Leukemia: Developed for the American Society of Hematology,” Blood, vol. 94, No. 5, Sep. 1, 1999, pp. 1517-1536.
Jean L. Grem, et al, “Cephalotaxine Esters: Antileukemic Advance or Therapeutic Failure,” Journal of the National Cancer Institute, vol. 80, No. 14, Sep. 21, 1988, pp. 1095-1103.
William J. Slichenmyer, MD, et al, “New Natural Products in Cancer Chemotherapy,” J. Clin. Pharmacol., vol. 30, 1990, pp. 770-788.
Alex J. Tipping, et al. Abstract #420, “Response of STI571-Resistant Cells to other Chemotherapeutic Drugs and Signal Transduction Inhibitors,” Molecular Pharmacology & Drug Resistance, p. 98a. (2003).
Barbara Scappini, et al. Abstract #425, “In Vitro Effects of STI571-Containing Drug Combinations on Growth of Ph-Positive Myelogenous Leukemia-Derived Cells,” Molecular Pharmacology & Drug Resistance, p. 99a. (2003).
Yasuhiko Kano, et al, “In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents,” Blood, vol. 97, No. 7, Apr. 1, 2001, pp. 1999-2007.
Barbara Scappini, MD, et al, “In Vitro Effects of STI 571-Containing Drug Combinations on the growth of Philadelphia-Positive Chronic Myelogenous Leukemia Cells,” Cancer, vol. 94, No. 10, May 15, 2002, pp. 2653-2662.
AJ Tipping, et al, “Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs,” Leukemia, vol. 16, 2002, pp. 2349-2357.
Z. Cai, et al, “Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation,” Leukemia, vol. 15, 2001, pp. 567-574.
Martin Sattler, et al, “The BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Histamine Cells,” The Journal of Biological Chemistry, vol. 275, No. 32, Aug. 11, 2000, pp. 24273-24278.
Metello Iacobini, et al, “Involvement of oxygen radicals in cytarabine-induced apoptosis in human polymorphonuclear cells,” Biochemical Pharmacology, vol. 61, 2001, pp. 1033-1040.
Kristoffer Hellstrand, et al, “Histamin and Cytokine Therapy,” Acta Oncologica, vol. 37, No. 4, 1998, pp. 347-353.
Ting-Chao Chou, et al, “Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors,” Adv. Enzyme Regul, vol. 22, 1984, pp. 27-55.
Gleevec™ (imatinib mesylate), Prescribing Information: Sponsor's Brochure T2002-97, 89012404, Dec. 2002, pp. 1-21, Novartis Pharma AG, Basle, Switzerland.
Blanchard Julie
Mahon François-Xavier
Maisonneuve Hervé
Maloisel Frederick
Robin Jean-Pierre
Buchanan & Ingersoll PC
Henley III Raymond J.
Stragen Pharma S.A.
LandOfFree
Treatment of chronic myelogenous leukmia, resistant or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of chronic myelogenous leukmia, resistant or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of chronic myelogenous leukmia, resistant or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3580732